Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7033877 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7033877 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO7033877 + Bronchoscopy | DRUG | Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3. |
Inclusion Criteria: * Male or female healthy volunteers, 18 to 55 years of age, inclusive. A female participant is eligible to participate if she is of non-childbearing potential defined as postmenopausal or surgically sterile * Healthy status is defined by absence of evidence of any active or chro...
RO7033877 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers, with a focus on measuring how the compound penetrates into the lung. It is not an approved medicine and remains in clinical development.
RO7033877 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the Phase 1 study of the compound in healthy volunteers. No other developer or partner is associated with the program based on the trial record.
RO7033877 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study enrolled 32 healthy volunteers and was conducted in the United States. The drug is investigational and has not been approved for any use.
RO7033877 has been evaluated in trial NCT02165293, titled a single center study to evaluate the penetration of RO7033877 into the lung in healthy volunteers. The Phase 1 trial enrolled 32 participants, was randomized, and has been completed. It was conducted in the United States.
RO7033877 has been studied in healthy volunteers rather than in a patient population, so no therapeutic indication has been disclosed. The completed Phase 1 trial, NCT02165293, assessed lung penetration of the compound. It is an investigational agent and is not approved for any indication.